Clinical Trials Browser

Phase 2 × Breast Neoplasms × dalpiciclib × Clear all

NCT07581834 2026-05-12

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Phase 2 Recruiting

Breast Diseases, Breast Neoplasms

NCT07539753 2026-04-30

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Breast Neoplasms

NCT07492394 2026-04-02

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06650748 2026-03-17

NeoMARS

Phase 2 Enrolling by invitation

Breast Neoplasms

NCT06970912 2026-01-21

DNADalHR

Phase 2 Recruiting

Breast Neoplasms

NCT07307287 2025-12-29

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05463601 2025-05-14

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06149130 2024-04-15

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06341894 2024-04-02

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

Phase 2 Recruiting

Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Phase 2 Unknown

Breast Neoplasms

NCT05800756 2023-04-06

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Phase 2 Unknown

Breast Neoplasms

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

Phase 2 Recruiting

Breast Neoplasms

NCT05512416 2022-08-23

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Phase 2 Unknown

Breast Neoplasms